141 related articles for article (PubMed ID: 25682545)
1. Concentrations of Erlotinib in Tumor Tissue and Plasma in Non-Small-Cell Lung Cancer Patients After Neoadjuvant Therapy.
Lankheet NA; Schaake EE; Burgers SA; van Pel R; Beijnen JH; Huitema AD; Klomp H;
Clin Lung Cancer; 2015 Jul; 16(4):320-4. PubMed ID: 25682545
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer.
Nishio M; Horiike A; Murakami H; Yamamoto N; Kaneda H; Nakagawa K; Horinouchi H; Nagashima M; Sekiguchi M; Tamura T
Lung Cancer; 2015 Jun; 88(3):275-81. PubMed ID: 25891541
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer.
Togashi Y; Masago K; Fukudo M; Terada T; Fujita S; Irisa K; Sakamori Y; Kim YH; Mio T; Inui K; Mishima M
J Thorac Oncol; 2010 Jul; 5(7):950-5. PubMed ID: 20479691
[TBL] [Abstract][Full Text] [Related]
4. Plasma and pleural fluid pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small-cell lung cancer with pleural effusion.
Masago K; Togashi Y; Fukudo M; Terada T; Irisa K; Sakamori Y; Kim YH; Mio T; Inui K; Mishima M
Clin Lung Cancer; 2011 Sep; 12(5):307-12. PubMed ID: 21775215
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of erlotinib in patients with advanced non‑small‑cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics.
Motoshima K; Nakamura Y; Sano K; Ikegami Y; Ikeda T; Mizoguchi K; Takemoto S; Fukuda M; Nagashima S; Iida T; Tsukamoto K; Kohno S
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1299-1304. PubMed ID: 24121455
[TBL] [Abstract][Full Text] [Related]
6. Quantitative determination of erlotinib and O-desmethyl erlotinib in human EDTA plasma and lung tumor tissue.
Lankheet NA; Schaake EE; Rosing H; Burgers JA; Schellens JH; Beijnen JH; Huitema AD
Bioanalysis; 2012 Nov; 4(21):2563-77. PubMed ID: 23173792
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
Yoshioka H; Hotta K; Kiura K; Takigawa N; Hayashi H; Harita S; Kuyama S; Segawa Y; Kamei H; Umemura S; Bessho A; Tabata M; Tanimoto M;
J Thorac Oncol; 2010 Jan; 5(1):99-104. PubMed ID: 19898258
[TBL] [Abstract][Full Text] [Related]
8. Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients.
Evelina Cardoso ; Guidi M; Khoudour N; Pascaline Boudou-Rouquette ; Fabre E; Tlemsani C; Arrondeau J; François Goldwasser ; Vidal M; Schneider MP; Wagner AD; Widmer N; Blanchet B; Csajka C
Clin Ther; 2020 Jul; 42(7):1302-1316. PubMed ID: 32631634
[TBL] [Abstract][Full Text] [Related]
9. Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.
Papadimitrakopoulou VA; Soria JC; Jappe A; Jehl V; Klimovsky J; Johnson BE
J Thorac Oncol; 2012 Oct; 7(10):1594-601. PubMed ID: 22968184
[TBL] [Abstract][Full Text] [Related]
10. Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non-Small-Cell Lung Cancer.
van Leeuwen RW; Peric R; Hussaarts KG; Kienhuis E; IJzerman NS; de Bruijn P; van der Leest C; Codrington H; Kloover JS; van der Holt B; Aerts JG; van Gelder T; Mathijssen RH
J Clin Oncol; 2016 Apr; 34(12):1309-14. PubMed ID: 26858332
[TBL] [Abstract][Full Text] [Related]
11. Mer receptor tyrosine kinase is frequently overexpressed in human non-small cell lung cancer, confirming resistance to erlotinib.
Xie S; Li Y; Li X; Wang L; Yang N; Wang Y; Wei H
Oncotarget; 2015 Apr; 6(11):9206-19. PubMed ID: 25826078
[TBL] [Abstract][Full Text] [Related]
12. Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment.
Parra-Guillen ZP; Berger PB; Haschke M; Donzelli M; Winogradova D; Pfister B; Früh M; Gillessen S; Krähenbühl S; Kloft C; Joerger M
Basic Clin Pharmacol Toxicol; 2017 Oct; 121(4):309-315. PubMed ID: 28444958
[TBL] [Abstract][Full Text] [Related]
13. Combined treatment with erlotinib and a transforming growth factor-β type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small-cell lung cancer cells.
Serizawa M; Takahashi T; Yamamoto N; Koh Y
J Thorac Oncol; 2013 Mar; 8(3):259-69. PubMed ID: 23334091
[TBL] [Abstract][Full Text] [Related]
14. Safety and CSF distribution of high-dose erlotinib and gefitinib in patients of non-small cell lung cancer (NSCLC) with brain metastases.
Shriyan B; Patil D; Gurjar M; Nookala M; Patil A; Kannan S; Patil V; Joshi A; Noronha V; Prabhash K; Gota V
Eur J Clin Pharmacol; 2020 Oct; 76(10):1427-1436. PubMed ID: 32529316
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA).
Kawaguchi T; Ando M; Asami K; Okano Y; Fukuda M; Nakagawa H; Ibata H; Kozuki T; Endo T; Tamura A; Kamimura M; Sakamoto K; Yoshimi M; Soejima Y; Tomizawa Y; Isa S; Takada M; Saka H; Kubo A
J Clin Oncol; 2014 Jun; 32(18):1902-8. PubMed ID: 24841974
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib.
Clark GM; Zborowski DM; Culbertson JL; Whitehead M; Savoie M; Seymour L; Shepherd FA
J Thorac Oncol; 2006 Oct; 1(8):837-46. PubMed ID: 17409968
[TBL] [Abstract][Full Text] [Related]
17. Erlotinib-based perioperative adjuvant therapy for a case of unresectable stage IIIA (N2) nonsmall cell lung cancer.
Wang Q; Wang H; Li P; Zhu H; He C; Wei B; Ma J; Ma Z
Am J Med Sci; 2010 Oct; 340(4):321-5. PubMed ID: 20601859
[TBL] [Abstract][Full Text] [Related]
18. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors.
Tolcher AW; LoRusso P; Arzt J; Busman TA; Lian G; Rudersdorf NS; Vanderwal CA; Kirschbrown W; Holen KD; Rosen LS
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1025-32. PubMed ID: 26420235
[TBL] [Abstract][Full Text] [Related]
19. Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model.
Li H; Wang S; Takayama K; Harada T; Okamoto I; Iwama E; Fujii A; Ota K; Hidaka N; Kawano Y; Nakanishi Y
Lung Cancer; 2015 Apr; 88(1):1-8. PubMed ID: 25670150
[TBL] [Abstract][Full Text] [Related]
20. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]